What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Biomica Raises $20M to Advance its Pipeline of Microbiome-based Therapeutics
What You Should Know:
- Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd raises $20M led by Shanghai Healthcare Capital (SHC).
- The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial; scale up and complete GMP
Read More
Q/A: Podimetrics CEO Talks Preventing Diabetic Amputations
Diabetes prevention is one of the biggest challenges in the healthcare industry as more than 37 million Americans (11.3% of the population) suffer from this debilitating chronic disease. As we close the year out, we sat down with Jon Bloom, MD, CEO and Co-founder of diabetic healthcare tech company Podimetrics to learn how the industry and his company are working to implement health equity change to serve patients living with advanced diabetes. The company’s FDA-cleared SmartMat provides a
Read More
Pangea Biomed Adds $5M for its Multi-Cancer Response Predictor
What You Should Know:
- Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in additional funding reaching a total seed round of $12M.
- The latest fundraising is led by angel investor Danny Tocatly and existing investor NFX, and will be used to expand US operations, drive commercial partnerships, and scale product offerings.
Expanding US Operations and Fostering Commercial
Read More
Half of Infusion Centers Struggling to Keep Up with Demand
What You Should Know:
- LeanTaaS, Inc., an AI-based predictive and prescriptive analytics company in healthcare operations, today announced its The State of Cancer Centers in 2022 Special Report, stemming from a survey conducted in partnership with The Association of Community Cancer Centers (ACCC) in mid-2022.
- With responses from nearly 100 cancer center leaders, hailing from hospitals and health systems across the country, the survey focuses on the operational challenges that infusion
Read More
Aetion, FDA to Evaluate Real-World Data Standardization for COVID-19
What You Should Know:
- Aetion, a provider of real-world evidence (RWE) technology and analytics, today announced that the FDA has extended Aetion’s contract to evaluate real-world data (RWD) involving COVID-19 medical countermeasures.
- Aetion will be expanding its work to evaluate data standardization in the context of COVID-19. Aetion has been collaborating with FDA since May 2020, providing validated software platform capabilities and RWD/E expertise to contribute to rapid evidence
Read More
Digital Health VCs Cite ROI & Clinical Validation As Greatest Markers of Company’s Success
What You Should Know:
- Investors in the healthcare technology space believe a measurable return on investment (ROI) and clinical validation of the technology's platform will be the greatest indicators of company success in 2023, according to a new survey of top digital health investors by GSR Ventures.
- ROI was deemed "important" or "very important" to the success of digital health companies by more than 94% of investor respondents, and 79% for clinical evidence and trials.
Top
Read More
AI Improving the Patient Experience of Cancer Care
For cancer patients and their loved ones, days, weeks, and months matter. In fact, anyone who has waited anxiously for test results or a treatment regimen to begin can attest that hours, or even minutes, will drag on with emotional heaviness. From a clinical standpoint as well, time to treatment significantly impacts outcomes. All suspected cancers should be ruled out or confirmed with a diagnosis so treatment can begin as soon as possible. Similarly, patients with incidental findings—masses or
Read More
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
RSNA: Philips Unveils AI-Enhanced Informatics Solutions to Optimize Radiology Workflow
What You Should Know:
- Today at RNSA22, Philips unveils its next-generation Advanced Visualization Workspace, including new cardiac MR Suite with new workflow and user interface, new AI powered CT ASPECT Scoring, and enhanced CT Liver Analysis applications.
- New integrated diagnostic approach connects radiology, cardiology, pathology, and oncology to securely unite data and images across the enterprise, enabling earlier and more definitive diagnosis. Optimized algorithms help speed up
Read More
